Ustekinumab, vedolizumab and Risankizumab. Anser testing was first launched in 2012 and has been cited in over 100 peer-reviewed publications or abstracts. Nearly 480,000 Anser tests have been ...

BENGALURU: Biocon Biologics, a biosimilars company and subsidiary of Biocon, has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a ...

Ustekinumab, vedolizumab and Risankizumab. Anser testing was first launched in 2012 and has been cited in over 100 peer-reviewed publications or abstracts. Nearly 480,000 Anser tests have been ...